{
  "scenario_id": "biotech_personalized_medicine_investment_2025",
  "context": "Mid-sized biotechnology company evaluating investment in personalized medicine platform using genomic sequencing and AI-driven treatment recommendations. Company has $50M in available capital and seeks to expand from traditional drug development into precision medicine.",
  "stakeholders": {
    "requester": "Chief Scientific Officer",
    "approvers": [
      "CEO",
      "CFO",
      "Board of Directors"
    ],
    "influencers": [
      "Head of R&D",
      "Chief Medical Officer",
      "VP of Business Development",
      "Regulatory Affairs Director"
    ]
  },
  "request": {
    "amount": "$25,000,000",
    "purpose": "Development and launch of personalized medicine platform including genomic sequencing capabilities, AI analytics engine, and clinical decision support tools",
    "urgency": "high",
    "justification": "Market opportunity in precision medicine estimated at $200B by 2030, with our platform addressing unmet needs in oncology and rare diseases. Expected 300% ROI within 5 years through subscription revenue and partnership deals."
  },
  "decision_process": [
    {
      "stage": "initial_review",
      "duration": "2 weeks",
      "activities": [
        "Technical feasibility assessment",
        "Market opportunity analysis",
        "Competitive landscape review"
      ],
      "outcome": "Advanced to detailed evaluation phase"
    },
    {
      "stage": "due_diligence",
      "duration": "6 weeks",
      "activities": [
        "Financial modeling and ROI analysis",
        "Regulatory pathway assessment",
        "Technology partner evaluation",
        "Clinical trial design review"
      ],
      "outcome": "Positive recommendation with conditions"
    },
    {
      "stage": "executive_review",
      "duration": "1 week",
      "activities": [
        "Board presentation",
        "Risk assessment discussion",
        "Strategic alignment evaluation"
      ],
      "outcome": "Approved with $20M allocation and milestone-based funding"
    }
  ],
  "business_impact": {
    "expected_outcome": "Establish company as leader in precision medicine, expand addressable market from $500M to $2B, create 150 new high-tech jobs",
    "projected_value": "$75,000,000 in cumulative revenue over 5 years",
    "risk_factors": [
      "Regulatory uncertainty in genomic data privacy",
      "Technology integration challenges with existing EHR systems",
      "Competition from tech giants entering healthcare",
      "Clinical validation timelines"
    ]
  },
  "decision_criteria": [
    "Strategic alignment with precision medicine trend",
    "Financial ROI potential",
    "Technical feasibility",
    "Regulatory compliance pathway",
    "Market timing and competitive advantage",
    "Resource availability and execution capability"
  ],
  "outcome": "Approved",
  "lessons_learned": "Early stakeholder engagement critical for complex platform investments. Milestone-based funding reduces risk while maintaining momentum. Regulatory affairs involvement from project inception essential for precision medicine initiatives."
}
